Traded Feb 19 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Jan 16, 2026 · Filed Jan 21, 2026
A United Therapeutics director sold $23K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$23,049
Shares × reported transaction price
79 days after results of Oct 29, 2025, 40 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.5% | +1.5% | −2.0% |
| 30 days | +0.8% | +0.6% | +0.2% |
| 90 days | +22.1% | +2.7% | +19.3% |
| 180 days | +12.7% | +8.3% | +4.4% |
Past results only. Not a forecast.
Traded Feb 19 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$290K of United Therapeutics
Scheduled in advancePaul A Mahon (EVP & GENERAL COUNSEL) sold ~$366K of United Therapeutics
Scheduled in advance